April 2, 2014
Dainippon Sumitomo Pharma (DSP) and Takeda Pharmaceutical said on March 31 that the European Commission has granted marketing authorization to their atypical antipsychotic agent Latuda (lurasidone) for adult schizophrenia. The authorization, given on March 21 local time, was based on...read more